Novartis, the company working on the investigational stem cell gene therapy trial for cystinosis, recently issued a Community Statement.

"The Novartis teams have been hard at work collaborating with the cystinosis community, cystinosis patient advocacy groups, cystinosis experts and health authorities to move the program forward since the Novartis acquisition of the investigational autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis from AVROBIO last year."

Read the full statement here.